Goldman Sachs’s AC Immune ACIU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $34.5K | Sell |
14,497
-7,135
| -33% | -$19.7K | ﹤0.01% | 6443 |
|
|
2026
Q1 | $59.5K | Buy |
21,632
+3,077
| +17% | +$9.6K | ﹤0.01% | 6279 |
|
|
2025
Q4 | $58.3K | Buy |
18,555
+5,920
| +47% | +$18.7K | ﹤0.01% | 6271 |
|
|
2025
Q3 | $36.5K | Buy |
12,635
+2,266
| +22% | +$5.12K | ﹤0.01% | 6201 |
|
|
2025
Q2 | $21K | Buy |
+10,369
| New | +$18K | ﹤0.01% | 5977 |
|
|
2024
Q4 | – | Sell |
-12,657
| Closed | -$47.8K | – | 5995 |
|
|
2024
Q3 | $47.8K | Sell |
12,657
-672
| -5% | -$2.35K | ﹤0.01% | 5635 |
|
|
2024
Q2 | $53.2K | Sell |
13,329
-10,280
| -44% | -$34K | ﹤0.01% | 5462 |
|
|
2024
Q1 | $69.9K | Buy |
23,609
+6,319
| +37% | +$22.7K | ﹤0.01% | 5288 |
|
|
2023
Q4 | $86.4K | Buy |
+17,290
| New | +$55.6K | ﹤0.01% | 5314 |
|
|
2023
Q1 | – | Sell |
-18,867
| Closed | -$38.5K | – | 5885 |
|
|
2022
Q4 | $38.5K | Sell |
18,867
-7,710
| -29% | -$19.9K | ﹤0.01% | 5629 |
|
|
2022
Q3 | $84K | Sell |
26,577
-2,305
| -8% | -$7.26K | ﹤0.01% | 5726 |
|
|
2022
Q2 | $104K | Buy |
28,882
+75
| +0.3% | +$257 | ﹤0.01% | 5850 |
|
|
2022
Q1 | $115K | Buy |
28,807
+2,184
| +8% | +$9.46K | ﹤0.01% | 6062 |
|
|
2021
Q4 | $132K | Sell |
26,623
-7,068
| -21% | -$41.1K | ﹤0.01% | 6045 |
|
|
2021
Q3 | $226K | Buy |
33,691
+292
| +0.9% | +$2.09K | ﹤0.01% | 5669 |
|
|
2021
Q2 | $265K | Sell |
33,399
-22,149
| -40% | -$153K | ﹤0.01% | 5592 |
|
|
2021
Q1 | $423K | Buy |
55,548
+3,959
| +8% | +$28.3K | ﹤0.01% | 5237 |
|
|
2020
Q4 | $267K | Buy |
51,589
+12,268
| +31% | +$62.6K | ﹤0.01% | 4941 |
|
|
2020
Q3 | $192K | Sell |
39,321
-19,271
| -33% | -$138K | ﹤0.01% | 4926 |
|
|
2020
Q2 | $394K | Buy |
58,592
+32,187
| +122% | +$234K | ﹤0.01% | 4493 |
|
|
2020
Q1 | $182K | Sell |
26,405
-14,675
| -36% | -$115K | ﹤0.01% | 4739 |
|
|
2019
Q4 | $350K | Buy |
41,080
+13,474
| +49% | +$89.8K | ﹤0.01% | 4688 |
|
|
2019
Q3 | $137K | Buy |
27,606
+4,291
| +18% | +$23K | ﹤0.01% | 4915 |
|
|
2019
Q2 | $129K | Sell |
23,315
-9,214
| -28% | -$47K | ﹤0.01% | 4885 |
|
|
2019
Q1 | $164K | Buy |
32,529
+5,338
| +20% | +$34K | ﹤0.01% | 4842 |
|
|
2018
Q4 | $257K | Buy |
+27,191
| New | +$257K | ﹤0.01% | 4708 |
|
|
2017
Q3 | – | Sell |
-14,475
| Closed | -$127K | – | 6632 |
|
|
2017
Q2 | $127K | Buy |
+14,475
| New | +$134K | ﹤0.01% | 6028 |
|
|
2017
Q1 | – | Sell |
-10,495
| Closed | -$136K | – | 6719 |
|
|
2016
Q4 | $136K | Sell |
10,495
-18,616
| -64% | -$258K | ﹤0.01% | 5994 |
|
|
2016
Q3 | $479K | Buy |
+29,111
| New | +$503K | ﹤0.01% | 5077 |
|
Other funds holding ACIU
Goldman Sachs's ACIU Position: Q2 2026 in Review
Goldman Sachs reduced its AC Immune (ACIU) stake by 33% in Q2 2026, selling an estimated $19.7K and leaving 14,497 shares worth $34.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6443.
Goldman Sachs first reported a position in ACIU in Q3 2016 and has held it in 29 quarters since. The position peaked at $479K in Q3 2016. 43 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.
- Goldman Sachs held 14,497 shares of AC Immune worth $34.5K as of Q2 2026.
- Goldman Sachs sold 7,135 AC Immune shares in Q2 2026, an estimated $19.7K.
- AC Immune made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6443 holding.
- Goldman Sachs first reported a position in AC Immune in Q3 2016 and has held it in 29 quarters since.
- Goldman Sachs's AC Immune position peaked at $479K in Q3 2016.
- 43 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.